home / stock / adap / adap news


ADAP News and Press, Adaptimmune Therapeutics plc From 05/15/24

Stock Information

Company Name: Adaptimmune Therapeutics plc
Stock Symbol: ADAP
Market: NASDAQ
Website: adaptimmune.com

Menu

ADAP ADAP Quote ADAP Short ADAP News ADAP Articles ADAP Message Board
Get ADAP Alerts

News, Short Squeeze, Breakout and More Instantly...

ADAP - Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M

2024-05-15 07:45:41 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics gets $125M in financing from Hercules Capital Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Qu...

ADAP - Adaptimmune gets $125M in financing from Hercules Capital

2024-05-15 07:36:21 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Quan...

ADAP - Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE ); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHE...

ADAP - Expected US Company Earnings on Wednesday, May 15th, 2024

Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...

ADAP - Adaptimmune Q1 2024 Earnings Preview

2024-05-14 13:24:59 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Quan...

ADAP - Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended ...

ADAP - Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

2024-04-26 11:00:11 ET Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Th...

ADAP - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

ADAP - Adaptimmune falls as Roche strategic collaboration ends

2024-04-12 08:53:13 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Seeking Alpha’s Quant Rating...

ADAP - Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4 th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18 th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. -...

Previous 10 Next 10